Prodotti competitors / Area Oncology 15 novembre 2024 AstraZeneca and Daiichi Sankyo announced the voluntary withdrawal of the US application of Dato-DXd (TROP2 ADC) for 2L+ locally advanced or metastatic non-squamous (Nsq) lung cancer (NSCLC)
Prodotti competitors / Area Oncology, Area Onco-Ema, Area COVID-19 Regulatory news / Area Oncology, Area Onco-Ema, Area COVID-19 15 novembre 2024 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
Normativa nazionale Regulatory news 15 novembre 2024 Conferenza Stato Regioni: in seduta straordinaria del 14 novembre 2024 rilasciato parere sullo schema di decreto per la serializzazione
Normativa europea Regulatory news 15 novembre 2024 New EDQM “Guidelines on medication review” based on medico-economic studies that provide full evidence of added value for public health and positive cost-benefit ratio
Prodotti competitors / Area Onco-Ema, Area Kite 15 novembre 2024 Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (NDMM)
Prodotti competitors / Area Onco-Ema, Area Kite 15 novembre 2024 Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Autorità nazionali / Area Liver Prodotti competitors / Area Liver 14 novembre 2024 NIce Recommendations : Elafibranor for previously treated primary biliary cholangitis
Autorità nazionali / Area Liver 13 novembre 2024 Epatite C: aggiornamento del 11 novembre 2024 sui pazienti arruolati
Prodotti competitors / Area Kite 13 novembre 2024 Liso-Cel therapy administered in the Outpatient community setting in patients with R/R Large B-Cell Lymphoma
Prodotti competitors / Area Kite 11 novembre 2024 FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
